Arthritis News and Research RSS Feed - Arthritis News and Research Twitter

Many people start to feel pain and stiffness in their bodies over time. Sometimes their hands or knees or shoulders get sore and are hard to move and may become swollen. These people may have arthritis. Arthritis may be caused by inflammation of the tissue lining the joints. Some signs of inflammation include redness, heat, pain, and swelling. These problems are telling you that something is wrong. Joints are places where two bones meet, such as your elbow or knee. Over time, in some types of arthritis but not in all, the joints involved can become severely damaged. There are different types of arthritis. In some diseases in which arthritis occurs, other organs, such as your eyes, your chest, or your skin, can also be affected. Some people may worry that arthritis means they won’t be able to work or take care of their children and their family. Others think that you just have to accept things like arthritis.
Newly discovered immune protein has potential  to stop or reverse type 1 diabetes

Newly discovered immune protein has potential to stop or reverse type 1 diabetes

Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed. [More]

UCLA study: Older men with multiple underlying health problems should avoid prostate cancer treatment

Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA Department of Urology. [More]
Common foot disorders are inherited, says Framingham Foot Study

Common foot disorders are inherited, says Framingham Foot Study

A novel study reports that white men and women of European descent inherit common foot disorders, such as bunions (hallux valgus) and lesser toe deformities, including hammer or claw toe. [More]
Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. [More]
New research reveals how endothelium maintains highly efficient barrier function

New research reveals how endothelium maintains highly efficient barrier function

The endothelium, the cellular layer lining the body's blood vessels, is extremely resilient. Measuring just a few hundred nanometers in thickness, this super-tenuous structure routinely withstands blood flow, hydrostatic pressure, stretch and tissue compression to create a unique and highly dynamic barrier that maintains the organization necessary to partition tissues from the body's circulatory system. [More]
Research reveals vitamin C does not reduce urate levels in gout patients

Research reveals vitamin C does not reduce urate levels in gout patients

Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitamin C supplementation, alone or in combination with allopurinol, appears to have a weak effect on lowering uric acid levels in gout patients according to the results published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism. [More]

RuiYi signs agreement with Genor BioPharma for development of RYI-008 in China

RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. [More]
Simponi injection gets FDA approval to treat adults with ulcerative colitis

Simponi injection gets FDA approval to treat adults with ulcerative colitis

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis. [More]

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients. [More]
Researchers uncover unique cellular, molecular mechanisms behind tooth renewal

Researchers uncover unique cellular, molecular mechanisms behind tooth renewal

Alligators may help scientists learn how to stimulate tooth regeneration in people, according to new research led by the Keck School of Medicine of the University of Southern California. [More]

Experts to give advice and guidance on managing pain among older adults

Older adults living with chronic pain, as well as their families and carers, have the opportunity to give their views to health experts at the University of Greenwich. [More]

Implications for manipulating immune response for some inflammatory disorders

Cytokines are molecules produced by immune cells that induce the migration of other cells to sites of infection or injury, promote the production of anti-microbial agents, and signal the production of inflammatory mediators. [More]

Drug cost disparities, small business worries continue to surround health law's implementation

The Associated Press reports on the emergence of concerns regarding the health law and drug cost disparities. Meanwhile, other news outlets report on how employers continue to have angst about the measure's price tag. [More]

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Biogen Idec announced today that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for the marketing approval of ELOCTATE (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A. [More]

Who is responsible for retired football players' medical costs?

Who should bear the costs of football-related medical problems that arise years after retirement? This question is at the heart of Williams's case -; and scores of others like it. [More]

Private insurers have cost Medicare almost $300 billion more over the life of the program

A study published online today finds that the private insurance companies that participate in Medicare under the Medicare Advantage program and its predecessors have cost the publicly funded program for the elderly and disabled an extra $282.6 billion since 1985, most of it over the past eight years. In 2012 alone, private insurers were overpaid $34.1 billion. [More]
Scientists identify new way to boost gene-silencing mechanism

Scientists identify new way to boost gene-silencing mechanism

A team led by scientists at The Scripps Research Institute (TSRI) has found how to boost or inhibit a gene-silencing mechanism that normally serves as a major controller of cells' activities. The discovery could lead to a powerful new class of drugs against viral infections, cancers and other diseases. [More]

Fat cells in knee secrete a protein linked to arthritis

Scientists have discovered that fat cells in the knee secrete a protein linked to arthritis, a finding that paves the way for new gene therapies that could offer relief and mobility to millions worldwide. [More]

First Edition: May 10, 2013

Todya's headlines include reports about efforts by the Obama administration to boost health exchange enrollment. [More]
FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced today that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older. [More]